ATXS (Astria Therapeutics Inc) Net Profit

ATXS (Astria Therapeutics, Inc.) - company brandmark

This chart of Astria Therapeutics (ATXS) earnings history on the GURU.Markets platform currently stands at -0.13. The business relies on strict temperature control during the transportation of complex biomolecules to medical centers. Astria Therapeutics (ATXS) develops agents to strengthen the body's defenses, overcoming the challenges of costly R&D and the patent protection of orphan drugs, which limits the market entry of new players.

ATXS (Astria Therapeutics) Net Profit history from 07/04/2022 to 02/07/2026

Analytical breakdowns and data insights for company Astria Therapeutics, Inc. (ATXS)

- price and consensus price forecast:
Stock Quotes Astria Corp|ATXS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Astria Corp|ATXS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Astria Therapeutics|ATXS - Book Capitalization|Market Capitalization to Book Value astriatx.com|ATXS - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Astria Therapeutics|ATXS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Astria Therapeutics Inc|ATXS - Company Total Debt|Debts to Book Capitalization Astria Corp|ATXS - Company Long-Term Debt|Company Short-Term Indebtedness Astria Therapeutics|Immediate Liquidity astriatx.com
- net income and valuation multiples indicators:
ATXS - Net Profit
Summary company analysis:Astria Therapeutics
Core merchandise of Astria Pharma

Astria Therapeutics (ATXS) develops innovative therapies for rare immune pathologies. Analyzing the company's financial performance, an investor can observe the dynamics of net daily income. This indicator separates the fundamental trend from random market noise, capturing the actual resilience of the business. For the pre-commercial sector, this metric reflects the burn rate prior to commercialization. Stable growth in these indicators minimizes default risk and confirms the viability of the strategy.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|PHAR - Net Profit|Nektar Therapeutics (NKTR) - Company Net Income|UPB - Net Financial Result|Net Income ZBIO|IMNM (Immunome Inc) - Profit After Payment of Taxes|Company Net Income Gossamer Corp (GOSS)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|Net Financial Result pieris.com (PVLA)|Savara - Net Profit|RIGL - Net Profit|ANAB (AnaptysBio Corp) - Net Income|enGene Corp - Final Profit|Net Income RAPT|JBIO (Aerovate) - Profit After Payment of Taxes|Net Profit ACRS|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Cabaletta Bio Inc (CABA) - Company Net Income|VTYX - Company Net Income|Final Profit THTX (theratech.com)|AVTX: Net Profit|Eledon Pharmaceuticals Inc. (ELDN) - Net Profit|Company Net Income Agenus Inc|Climb Bio, Inc - Profit After Tax|Net Profit ZURA|ATYR - Company Net Income|Adagene Inc. - Net Income|Net Profit ImageneBio IMA|STTK: Net Income|Equillium, Inc. - Profit After Payment of Taxes|CNTB: Net Profit|IMUX - Net Financial Result|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Income InflaRx GmbH (IFRX)|Company Net Income X4 Pharma (XFOR)|Net Financial Result adicetbio.com|Net Profit CELU (Celularity)|Net Profit inmunebio.com INMB|BRNS: Net Income|Kezar Life Sciences Inc. - Profit After Payment of Taxes|SABS (SAB Biotherapeutics, Inc) - Net Income|Company Profit AKTX|Company Net Income Enlivex Therapeutics Ltd|Q32 Bio Corp (QTTB) - Net Financial Result|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit